StockData
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. (MBRX) stock

MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$6.75−0.08 (-1.17%)

Close on Nov 18, 2026Market cap $131.47MP/E –Yield –

Moleculin Biotech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Moleculin Biotech's operating income for the twelve months ending Jun 30, 2026 was -$28.87M. For fiscal 2025 it was -$25.10M. The highest annual figure on record is -$3.88M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.10M–
FY2024Dec 31, 2024-$26.64M–
FY2023Dec 31, 2023-$29.63M–
FY2022Dec 31, 2022-$30.64M–
FY2021Dec 31, 2021-$22.97M–
FY2020Dec 31, 2020-$19.74M–
FY2019Dec 31, 2019-$17.52M–
FY2018Dec 31, 2018-$15.03M–
FY2017Dec 31, 2017-$8.65M–
FY2016Dec 31, 2016-$3.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.56M–
Q1 FY2026Mar 31, 2026-$7.87M–
Q4 FY2025Dec 31, 2025-$7.53M–
Q3 FY2025Sep 30, 2025-$5.91M–
Q2 FY2025Jun 30, 2025-$5.72M–
Q1 FY2025Mar 31, 2025-$5.94M–
Q4 FY2024Dec 31, 2024-$6.64M–
Q3 FY2024Sep 30, 2024-$7.14M–
Q2 FY2024Jun 30, 2024-$6.19M–
Q1 FY2024Mar 31, 2024-$6.68M–
Q4 FY2023Dec 31, 2023-$8.92M–
Q3 FY2023Sep 30, 2023-$5.95M–
Q2 FY2023Jun 30, 2023-$6.41M–
Q1 FY2023Mar 31, 2023-$8.35M–
Q4 FY2022Dec 31, 2022-$7.05M–
Q3 FY2022Sep 30, 2022-$9.08M–
Q2 FY2022Jun 30, 2022-$7.43M–
Q1 FY2022Mar 31, 2022-$7.07M–
Q4 FY2021Dec 31, 2021-$5.21M–
Q3 FY2021Sep 30, 2021-$6.16M–
Q2 FY2021Jun 30, 2021-$5.52M–
Q1 FY2021Mar 31, 2021-$6.09M–
Q4 FY2020Dec 31, 2020-$3.50M–
Q3 FY2020Sep 30, 2020-$6.15M–
Q2 FY2020Jun 30, 2020-$5.03M–
Q1 FY2020Mar 31, 2020-$5.06M–
Q4 FY2019Dec 31, 2019-$4.81M–
Q3 FY2019Sep 30, 2019-$4.51M–
Q2 FY2019Jun 30, 2019-$3.63M–
Q1 FY2019Mar 31, 2019-$4.57M–
Q4 FY2018Dec 31, 2018-$4.34M–
Q3 FY2018Sep 30, 2018-$2.59M–
Q2 FY2018Jun 30, 2018-$5.46M–
Q1 FY2018Mar 31, 2018-$2.64M–
Q4 FY2017Dec 31, 2017-$3.39M–
Q3 FY2017Sep 30, 2017-$2.40M–
Q4 FY2016Dec 31, 2016-$1.42M–
Q3 FY2016Sep 30, 2016-$1.42M–
Q2 FY2016Jun 30, 2016-$724.00K–

More Moleculin Biotech figures

See a number that looks wrong?